ArticleMolecular nutrition & food research2025
Saucerneol Inhibits the Growth, Migration, and Invasion of Osteosarcoma Cells In Vitro and Prevents Metastasis-Associated Osteolysis Ex Vivo.
Article in Molecular nutrition & food research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Saucerneol Inhibits the Growth, Migration, and Invasion of Osteosarcoma Cells In Vitro and Prevents Metastasis-Associated Osteolysis Ex Vivo.Molecular nutrition & food research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Saururus chinensis has traditionally been used to treat various diseases. Biologically active compounds isolated from S. chinensis exhibit diverse pharmacological activities. The aim of this study was to investigate the antiosteosarcoma effects of saucerneol (Sauc), a lignan, purified from the aerial parts of S. chinensis using in vitro and ex vivo experimental models. Sauc was purified from the methanolic extract of S. chinensis. It exhibited toxicity against MG63 and SJSA-1 cells (human osteosarcoma cell lines), inducing apoptotic morphological changes and suppressing cell migration. Sauc triggered PARP cleavage and decreased the expression of antiapoptotic proteins. It also disrupted mitochondrial membrane potential and increased reactive oxygen species (ROS) generation. Proteome profiling, western blotting, and immunocytochemistry revealed that Sauc inhibited the JAK2/STAT3 pathway. Furthermore, Sauc downregulated the expression of metastasis-associated proteins, suppressed invasion through extracellular matrix-coated membranes, and inhibited anchorage-independent cell growth. In an ex vivo bone organ culture, Sauc attenuated tumor-induced osteolysis. This study demonstrated that Sauc exerts anti-osteosarcoma effects by inducing apoptosis, inhibiting cell migration and invasion in vitro, and mitigating metastasis-associated bone degradation ex vivo. Thus, Sauc holds promise as a protective compound in daily health supplements and a therapeutic agent against human osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.